Impax Asset Management Group plc trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 67.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 66,574 shares of the company’s stock after selling 137,620 shares during the period. Impax Asset Management Group plc’s holdings in Merck & Co., Inc. were worth $9,674,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of MRK. BlackRock Inc. lifted its holdings in Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after acquiring an additional 1,073,507 shares during the last quarter. State Street Corp lifted its holdings in Merck & Co., Inc. by 0.9% in the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after acquiring an additional 1,087,583 shares during the last quarter. Wellington Management Group LLP boosted its stake in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after acquiring an additional 1,934,312 shares during the period. Fisher Asset Management LLC boosted its stake in Merck & Co., Inc. by 8.3% in the third quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company’s stock valued at $6,059,345,000 after acquiring an additional 3,183,169 shares during the period. Finally, Bank of America Corp DE boosted its stake in Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after acquiring an additional 2,919,780 shares during the period. 76.07% of the stock is currently owned by institutional investors.
Insider Activity at Merck & Co., Inc.
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total value of $8,611,961.85. Following the sale, the executive vice president owned 112,955 shares in the company, valued at approximately $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.17% of the company’s stock.
Analyst Ratings Changes
Several equities analysts have recently commented on the company. Citigroup upped their target price on Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a report on Monday, October 12th. The Goldman Sachs Group raised their price target on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Guggenheim raised their price target on Merck & Co., Inc. from $170.00 to $171.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Sanford C. Bernstein boosted their price objective on Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a research report on Tuesday, August 4th. Finally, Argus started coverage on Merck & Co., Inc. in a research report on Tuesday, November 3rd. They set a “strong-buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $155.74.
Check Out Our Latest Stock Report on MRK
Key Merck & Co., Inc. News
Here’s some of the latest news about MRK:
- Positive Sentiment: Merck raised its quarterly dividend 3.5%, from $0.85 to $0.88 per share, equivalent to $3.52 annually. The increase may appeal to income-focused investors. Merck Announces First-Quarter 2027 Dividend
- Positive Sentiment: A comparison with Bristol Myers Squibb characterized Merck as the stronger investment, citing its stock performance, oncology position, pipeline expansion and diversified growth drivers. Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?
- Neutral Sentiment: Thomas H. Glocer plans to retire from Merck’s board in May 2027, with Douglas M. Baker Jr. appointed independent lead director. The leadership transition is scheduled for next year. Board of Directors Update
Merck & Co., Inc. Stock Down 3.9%
Merck & Co., Inc. stock opened at $137.75 on Thursday. The company has a 50-day simple moving average of $145.73 and a 200-day simple moving average of $129.11. The firm has a market capitalization of $339.59 billion, a P/E ratio of 142.01, a P/E/G ratio of 6.57 and a beta of 0.13. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35. Merck & Co., Inc. has a one year low of $93.90 and a one year high of $156.92.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.58 EPS. As a group, equities analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current year.
Merck & Co., Inc. Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, January 8th. Shareholders of record on Tuesday, December 15th will be given a $0.88 dividend. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.85. The ex-dividend date is Tuesday, December 15th. This represents a $3.52 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is currently 350.52%.
Merck & Co., Inc. Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Featured Stories
- Five stocks we like better than Merck & Co., Inc.
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
